Efficacy and toxicity of nimotuzumab combined with radiotherapy in elderly patients with esophageal squamous cell carcinoma

about

Radiotherapy Alone or Concurrent Chemoradiation for Esophageal Squamous Cell Carcinoma in Elderly Patients.

P2860

Q47139282-4865F4B3-70AC-441B-90BC-555FF8F2BCF7

P2860

Efficacy and toxicity of nimotuzumab combined with radiotherapy in elderly patients with esophageal squamous cell carcinoma

Item

http://www.wikidata.org/entity/Q35948006

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Efficacy and toxicity of nimot ...... hageal squamous cell carcinoma

@ast

Efficacy and toxicity of nimot ...... hageal squamous cell carcinoma

@en

type

Item

label

Efficacy and toxicity of nimot ...... hageal squamous cell carcinoma

@ast

Efficacy and toxicity of nimot ...... hageal squamous cell carcinoma

@en

prefLabel

Efficacy and toxicity of nimot ...... hageal squamous cell carcinoma

@ast

Efficacy and toxicity of nimot ...... hageal squamous cell carcinoma

@en

P1476

Efficacy and toxicity of nimot ...... hageal squamous cell carcinoma

@en

P2093

Ben-Hua Xu

http://www.w3.org/2001/XMLSchema#string

Cheng Chen

http://www.w3.org/2001/XMLSchema#string

Hai-Jie Lu

http://www.w3.org/2001/XMLSchema#string

Jin-Hua Guo

http://www.w3.org/2001/XMLSchema#string

Ming-Qiu Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.

Is there a benefit in receiving concurrent chemoradiotherapy for elderly patients with inoperable thoracic esophageal squamous cell carcinoma?

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer

HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.

Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial.

P304

1135-1138

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/MCO.2015.606

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281978807

http://www.w3.org/2001/XMLSchema#string

P698

26623065

http://www.w3.org/2001/XMLSchema#string

P932

4534853

http://www.w3.org/2001/XMLSchema#string

Efficacy and toxicity of nimotuzumab combined with radiotherapy in elderly patients with esophageal squamous cell carcinoma

about

P2860

P2860

Efficacy and toxicity of nimotuzumab combined with radiotherapy in elderly patients with esophageal squamous cell carcinoma

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932